
    
      Subjects will be enrolled in the study for a maximum of 43 days, including an optional 14-day
      screening period, 28 days of active product administration, and followed by a post-treatment
      follow-up within 1 day.

      The primary objective of this study is:

        -  To evaluate the safety of PG-DN-20WS for the treatment of painful DPN of the feet
           compared to a placebo control, including emergence of suicidal thoughts.

      The secondary objectives of this study are:

        -  To evaluate the impact of PG-DN-20WS on subject's neuropathic pain, anxiety, and sleep
           quality compared to a placebo control.

        -  To evaluate the impact of PG-DN-20WS on the subject's impression of their response to
           the treatment compared to a placebo control.
    
  